Why the study?
Do fibrinolytic agents (urokinase and streptokinase) improve outcomes and have acceptable safety compared to traditional anticoagulants in patients with deep-vein thrombosis and pulmonary embolism?
Population
Carefully selected patients with deep-vein thrombosis and pulmonary embolism
Comparison
Fibrinolytic agents (urokinase and streptokinase) vs Traditional anticoagulants (heparin sodium)
Design
Guideline
Authors
Loading...
Urges greater use of urokinase or streptokinase over heparin for DVT and PE; reinforces consensus favoring fibrinolysis in venous thromboembolism.
Do fibrinolytic agents (urokinase and streptokinase) improve outcomes and have acceptable safety compared to traditional anticoagulants in patients with deep-vein thrombosis and pulmonary embolism?
An NIH consensus panel urges greater use of fibrinolytic agents (urokinase and streptokinase) over heparin for DVT and PE, citing superior long-term benefits and acceptable bleeding risks.
John F. Elliott (1980) studied deep-vein thrombosis and pulmonary embolism. urokinase and streptokinase vs. traditional anticoagulants (heparin sodium) was evaluated. Urokinase and streptokinase were concluded by an NIH consensus panel to be safe and more effective than traditional anticoagulants for treating deep-vein thrombosis and pulmonary embolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: